Insurance-First GLP-1 Access
Found Launches $99 GLP-1 Plans, Prioritizing Insurance for Weight Loss
Anonymous
Found, a telehealth weight loss platform, is offering its first month of service for $99 — a $100 discount off its regular price — as it bets on an "insurance-first" model to make GLP-1 weight loss drugs more accessible Naples Daily News. The company connects patients with licensed medical providers and then works to get GLP-1 medications like Wegovy and Zepbound covered through a patient's existing health insurance, potentially reducing drug costs from over $1,000 per month to a standard copay.
Found says its clinical care network is now in-network for more than 100 million insured Americans, covering plans from Aetna, Anthem Blue Cross Blue Shield, Cigna, and UnitedHealthcare Herald Tribune. When insurance applies, the monthly membership fee can drop as low as $17.
How Found's Insurance-First Model Actually Works
Most telehealth platforms sell GLP-1 prescriptions directly for cash. Found takes a different approach. It starts every new member with a short health assessment. Then its medical team reviews the patient's history and recommends a treatment plan Des Moines Register. A dedicated insurance team handles prior authorizations — the paperwork insurers require before approving expensive drugs — and files appeals if coverage is denied.
If insurance comes through, patients pay standard pharmacy copays, often $25 to $50, instead of the full retail price. The $99 monthly fee covers clinical visits, behavioral coaching, and virtual check-ins — but not the medication itself Asbury Park Press. That distinction matters: the subscription and the drug are billed separately.
A 66,000-Patient Study Backs the Generic Drug Option
Not every patient can get a GLP-1 covered by insurance. For those who can't, Found offers an alternative backed by real data. In January 2025, the company published a peer-reviewed study of 66,000 patients in the journal Obesity Science & Practice Lansing State Journal. It found that 88% of patients achieved clinically significant weight loss using low-cost generic drugs like metformin and naltrexone — not brand-name GLP-1s.
Patients on GLP-1 medications lost an average of 13.9% of their body weight over 12 months. Those on the cheaper generic regimens lost 7.9% Ventura County Star. Found's Chief Medical Officer, Dr. Rekha Kumar, put it plainly: "Wouldn't we rather have the majority of people lose 8% and get healthier, than a sliver of the population lose 20% and the rest of the population remain unhealthy?"
Insurers Are Pulling Back Just as Demand Surges
The timing is tricky. As Found expands its insurance network, some major insurers are moving in the opposite direction. Blue Cross Blue Shield of Massachusetts dropped routine coverage for weight-loss GLP-1 drugs at the start of 2026 Tuscaloosa News. Other carriers are following. Insurers worry that covering $1,000-per-month drugs for the roughly 40% of U.S. adults with obesity could push premiums higher for everyone.
Patient advocates warn of a "bait-and-switch" risk. People pay months of non-refundable subscription fees only to have the drug denied by their insurer TCPalm. Found CEO Luca Ranaldi has argued the company is helping solve this problem by working inside the system rather than around it, saying the goal is "addressing critical health equity disparities and proving that effective weight care can be more accessible and cost-effective."
What Comes Next for Low-Cost GLP-1 Access
Competition is heating up. Rivals like Noom and WeightWatchers launched competing $99 programs in mid-2026 Journal & Courier. On July 1, 2026, the federal government launched the Medicare GLP-1 Bridge program, offering covered GLP-1 medications for a flat $50 monthly copay to eligible beneficiaries — a move that could pressure private insurers to set similar cost caps.
Found also expanded in May 2025 to support manufacturer pharmacy programs like LillyDirect and NovoCare, letting its doctors prescribe Wegovy and Zepbound at reduced cash-pay retail rates for patients whose insurance falls short Peoria Journal Star. The company is betting that pairing clinical care with aggressive insurance navigation is the most durable path to scale — even as the rules keep changing around it.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
30
Articles
29
Reach
30
A
AnonymousAuthor